THCA Therapeutics traces its origins back to 2016, when founder Farbod Parvin began exploring the therapeutic potential of tetrahydrocannabinolic acid (THCA). Personal observations and a growing interest in cannabinoid science inspired the long-term vision of developing pharmaceutical-grade, non-intoxicating cannabinoid medicines capable of addressing chronic inflammatory diseases. This marked the beginning of a scientific journey that would later evolve into THCA Therapeutics.